(19)
(11) EP 2 395 012 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.06.2018 Bulletin 2018/23

(45) Mention of the grant of the patent:
18.04.2018 Bulletin 2018/16

(21) Application number: 11169865.0

(22) Date of filing: 02.11.2006
(51) International Patent Classification (IPC): 
A61K 48/00(2006.01)
C12N 15/113(2010.01)
C12N 15/11(2006.01)
 A61K 31/713(2006.01)
A61K 9/127(2006.01)

(54)

Modified siRNA molecules and uses thereof

Modifizierte siRNA-Moleküle und Verwendungen davon

Molécules d'ARNsi modifiées et leurs utilisations

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 02.11.2005 US 732964 P
30.06.2006 US 817933 P

(43) Date of publication of application:
14.12.2011 Bulletin 2011/50

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06804676.2 / 1948674

(73) Proprietor: Arbutus Biopharma Corporation
Vancouver BC V7Y 1B3 (CA)

(72) Inventors:
  • MacLachan, Ian
    Mission, British Columbia V4S 1E5 (CA)
  • Judge, Adam
    Vancouver, British Columbia V6J 2C6 (CA)

(74) Representative: J A Kemp 
14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A-2004/029212
WO-A2-2004/090105
 WO-A-2004/046324
US-A1- 2005 119 214
   
  • MORRISSEY DAVID V ET AL: "Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 8, 1 August 2005 (2005-08-01) , pages 1002-1007, XP002452540, ISSN: 1087-0156
  • HORNUNG V ET AL: "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 11, no. 3, 20 February 2005 (2005-02-20), pages 263-270, XP002371477, ISSN: 1078-8956, DOI: 10.1038/NM1191
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).